BioSpace News Archive

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Science.

Aditxt, Inc., a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it will effect a 1-for-40 reverse split of its common stock.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 189,850 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the final 510(k) clearance from the FDA for the Integrity™ Implant System.

MediciNova, Inc., today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.

GC Biopharma announced on August 17, 2023 that it has presented the results of analyzing and comparing thrombotic adverse events of Hemlibra and Factor FVIII replacements reported in the US Food and Drug Administration Adverse Event Reporting System at the Bleeding Disorder Conference currently being held in Maryland, U.S. from August 17 to August 19, 2023.

August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical’s iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at the conference.

TheracosBio and SmithRx, a next-generation pharmacy benefits management (PBM) company, today announced that SmithRx will offer access to BRENZAVVY™ (bexagliflozin), TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes, through its partnership with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs).

GSK plc (LSE/NYSE: GSK) today announced that AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the US at all major retail pharmacies.

Akston Biosciences Corporation announced today that it will focus on inventing, developing, and manufacturing breakthrough protein therapeutics for Companion Animal Health, utilizing its versatile Ambifect™ Fc-fusion platform and its Beverly, Massachusetts cGMP biologics manufacturing facility.